2023 has been complete with numerous innovations in the dermatology space, including in atopic dermatitis, psoriasis, alopecia areata, and more.
The end-of-the-year rush, although seemingly hectic, is an opportunity to reflect on the numerous innovations in dermatology that were new in 2023. Just in the past few months, the FDA approved roflumilast cream 0.3% (Zoryve) for children aged 6 to 11 years with psoriasis, VP-102 (Ycanth) for the treatment of molluscum contagiosum, ritlecitinib (Litfulo) for adolescents with severe alopecia areata, and more. With so many new additions to the dermatology armamentarium, and more to come, clinicians and patients have many therapeutic options to be thankful for.
Atopic dermatitis has been in the spotlight often this year as new agents continue to advance through clinical trial phases. One consideration that is frequently discussed at meetings and among colleagues is the difference in available therapeutic options for atopic dermatitis between adults and children. This month’s cover feature dives more into the differences between adult and pediatric atopic dermatitis, featuring expert insights from Raj Chovatiya, MD, PhD; and Lawrence Eichenfield, MD.
November is also no stranger to awareness months. In this issue of Dermatology Times, we spotlight National Healthy Skin Month, Hyperhidrosis Awareness Month, and National Native American Heritage Month. Mara Weinstein-Velez, MD, reviews her top recommended cosmetic procedures to promote healthy skin; Sue Ellen Cox, MD, explains misconceptions regarding hyperhidrosis; and Lucinda Kohn, MD, discusses caring for Native American and Indigenous patients who face socioeconomic and geographic barriers to dermatologic care.
Dermatology Times has been on the road throughout the busy travel season to bring late-breaking data and treatment pearls to our readers. In this month’s conference coverage section, you’ll find the latest updates from Maui Derm NP+PA Fall, which was held in Asheville, North Carolina; Fall Clinical Dermatology Conference, which was held in Las Vegas, Nevada; and the inaugural 2023 Inflammatory Disease Summit, also held in Las Vegas in conjunction with Fall Clinical.
To keep up with the latest updates in breaking news, treatment pearls, study data, and interviews with experts in the field, subscribe to Dermatology Times e-newsletters, follow us on social media, and email us at DTEditor@mmhgroup.com to share your insights.
Mike Hennessy Jr
President and CEO, MJH Life Sciences